Compare MXCT & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | CHPT |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.2M | 143.0M |
| IPO Year | 2021 | 2019 |
| Metric | MXCT | CHPT |
|---|---|---|
| Price | $1.24 | $9.85 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | $5.50 | ★ $9.25 |
| AVG Volume (30 Days) | 403.0K | ★ 3.6M |
| Earning Date | 05-12-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $33,026,000.00 | ★ $411,224,000.00 |
| Revenue This Year | N/A | $4.18 |
| Revenue Next Year | $18.50 | $16.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $4.44 |
| 52 Week High | $1.86 | $12.61 |
| Indicator | MXCT | CHPT |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 64.69 |
| Support Level | $1.19 | $5.47 |
| Resistance Level | $1.30 | $10.43 |
| Average True Range (ATR) | 0.05 | 0.89 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 54.29 | 80.47 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.